ArticleFrontiers in immunology2023

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.

Lorenz Kocheise et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.